Rivaroxaban does not cure blood clots, but mainly prevents them from forming. Rivaroxaban is a highly selective, oral drug that directly inhibits coagulation factor Xa. It can interrupt endogenous and exogenous coagulation pathways, thus inhibiting the production of thrombin and achieving the purpose of avoiding thrombus formation. However, rivaroxaban is not a thrombolytic agent and is not able to dissolve the thrombus that has already formed, thus it does not cure the thrombus that has already formed. Human blood clots are mainly composed of insoluble fibrin, platelets, white blood cells and red blood cells. When a blood clot first starts to form, it can currently be treated with thrombolytic agents, such as urokinase and streptokinase, which have the potential to dissolve the clot away, thus curing it. Alternatively surgery can be done to remove the blood clot. Therefore, for patients with thrombus, after thrombolysis or thrombus removal, rivaroxaban can be taken to prevent re-formation of thrombus, which is especially effective in preventing venous thrombosis in the lower limbs. It should be noted that not all people are suitable for taking rivaroxaban. Rivaroxaban should not be taken by patients who are allergic to the drug components, have active bleeding, have coagulation abnormality and clinically relevant bleeding risk of liver disease, as well as by pregnant women and nursing mothers. Rivaroxaban needs to be administered strictly according to the doctor’s instructions. In the event of a blood clot, seek immediate medical attention and treatment as prescribed.